What is the purpose? [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2016-05-03 12:43 (2044 d 23:04 ago) – Posting: # 16268
Views: 7,131

Hi M.tareq,

» […] performing stat analysis of a 4 period 4 seq 3 treatment partial replicate Cross over study, where the ref product only replicate against t1 and t2 for a bioequivlence study of sofosbuvir?

Can you give us an example how the sequences would look like? What is the purpose of having two Test-products in the study? See also this post and followings.

» The FDA recommendation is for full replicate…

No it isn’t. The FDA recommends two conventional 2×2×2 studies (fasting and fed state).

According to the WHO’s PQTm the reference in fed state is a HVDP (Cmax CVwR 54%) whilst variability of AUC is low (CVwR 10%). In the WHO’s guidance reference-scaling for Cmax according to the EMA’s method is mentioned as an alternative.

» …and there are little information found regarding a 4 period Cross over with partial replication?

I have never heard about such a design.

» What other effects to account for beside the usual fixed effects in traditional 2x2 Cross over?

No idea.

» Within subject effect, within formulation variability, and carry over effect?

The sequence effect is confounded withA statistically significant sequence effect could indicate that there isIt cannot be handled statistically but only avoided by design (sufficient wash-out). Including carry-over in cross-overs does not make sense.

» Newbie in stat...

You mentioned Sas proc mixed in the subject line. If you want to apply the EMA’s ABEL, a mixed-effects model is not acceptable. If you want to apply the FDA’s RSABE, the partial replicate for the unscaled PK metric (AUC) may fail to converge. Specify the covariance structure with TYPE=FA0(1) instead of TYPE=FA0(2) as given in the progesterone guidance.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,788 posts in 4,557 threads, 1,548 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time: Wednesday 10:48 CET (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz